Limbrel Medication Linked to Potentially Life-Threatening Health Issues

The medication Limbrel is allegedly causing serious life-threatening issues for users. The FDA is investigating this drug, a prescription product to help meet nutritional requirements of patients with osteoarthritis. Among many serious adverse events, two severe injuries are drug-induced liver injury and hypersensitivity pneumonitis.

The FDA received 194 adverse event reports related to the use of Limbrel. Of these, 57 cases have sufficient information that the FDA will use to analyze whether Limbrel was the actual cause of the adverse event. 30 of the 194 cases have sufficient information to apply the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method. This method is used to determine the likelihood that there is an association between Limbrel and the reported adverse event.

GoldenbergLaw has over 30 years of experience handling dangerous drugs and is committed to holding drug manufacturers and suppliers responsible in these circumstances. Contact Senior Partner Stuart Goldenberg for any questions on Limbrel or other dangerous drugs and supplements.


We Truly Care

The GoldenbergLaw Difference
  • Kindness Is Strength.

    With us, you matter most. This team spends the time to ensure clients like you get to rest and leave the sleepless nights to us.

  • Accountability Is Bravery.

    We live and breathe what we do, and we don't stop until the responsible party is held liable.

  • Leadership Is Trust.

    Our firm has been trusted to lead roles within some of the nation's largest litigations.

  • Knowledge Is Power.

    Our firm is focused on the science of the case and applying it to helping our clients recover.

Contact Us

We Focus On What You Need
  • Please enter your first name.
  • Please enter your last name.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your email address.
    This isn't a valid email address.
  • Please make a selection.
  • Please enter a message.